Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Propanc Biopharma's board approved a 1-for-10 reverse stock split, effective before market open in late October 2026, with shares continuing to trade under ticker PPCB under a new CUSIP (74346N883). The company stated the split is intended to restore compliance with Nasdaq's $1.00 minimum bid price requirement and support future growth plans.
Key figures
- New cusip
- 74346N883
- Effective date
- October 26, 2026 (article also states October 19, 2026 in a later paragraph)
- Reverse split ratio
- 1-for-10
- Shares outstanding pre split
- approximately 10,331,116 million shares (as stated, as of October 8, 2026)
- Shares outstanding post split
- approximately 1,033,112 million shares (as stated, pro forma)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.